Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells

Figure 6

Expression of relevant signaling molecules following treatment with galectin-3 inhibitors (GB1107 and TD139) in FTC-133 and 8505C human thyroid cancer cells. The protein expression was determined using immunoblotting after 24-h treatment.